Theragnostic Technologies exhibited at Stony Brook's office of Economic Development second annual incubator showcase, Thursday, June 8th. Over 50 company exhibited including representation from the biotechnology, energy and IT industries.
Theragnostic Technologies Inc has been selected for prestigious NIH Commercialization Accelerator Program (CAP). CAP offered annually since 2004 is designed to help some of NIH’s most promising healthcare Phase II grantees. Applicants are selected via a competitive process for a limited number of slots.
Theragnostic Technologies first product ManGraDex is featured on Research Foundation (RF) of State University of New York (SUNY) website. It discussed on the impact of two business development programs—SUNY’s Technology Accelerator Fund (TAF) and START-UP NY on the development of early stage biomedical technologies.
Theragnostic Technologies has received Small Business Innovation Research (SBIR) Phase 2 grant from the National Institute of Diabestes and Digestive and Kidney Diseases. This SBIR phase 2 project focuses on preclinical investigational new drug (IND) enabling studies of a novel high performance carbon nanostructure-ased magnetic resonance imaging (MRI) contrast agent (CA) to be used to diagnose and monitor patients with renal failure.
Theragnostic Technologies will be introducing ManGraDex MRI technology at the TechConnect Innovation Showcase and Accelerator program, the World’s largest showcase and accelerator for industry-vetted emerging-technologies ready for commercialization. We are seeking to connect with investors and development partners.
Governor Andrew M. Cuomo today announced that Theragnostic Technologies is one of the ten businesses to receive START-UP NY status. Theragnostic joins more than 80 companies already participating in the innovative program that creates tax-free areas associated with colleges and universities across the state.
Theragnostic Technologies has received Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Diabestes and Digestive and Kidney Diseases in collaboration with Stony Brook University. This STTR phase 1 proposal investigates the safety and efficacy of a novel high-performance carbon nanostructure-based magnetic resonance imaging (MRI) contrast agent for the imaging and monitoring of patients with renal failure.
Dr. Balaji Sitharaman, PhD, an Assistant Professor in the Department of Biomedical Engineering at Stony Brook University, and a team of researchers developed a new, highly efficacious, potentially safer and more cost effective nanoparticle-based MRI (magnetic resonance imaging) contrast agent for improved disease diagnosis and detection.